These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis. Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Mahurkar S; Suppiah V; O'Doherty C Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284 [TBL] [Abstract][Full Text] [Related]
4. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350 [TBL] [Abstract][Full Text] [Related]
5. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients. Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047 [TBL] [Abstract][Full Text] [Related]
6. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Yong VW Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849 [TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Ragheb S; Abramczyk S; Lisak D; Lisak R Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193 [TBL] [Abstract][Full Text] [Related]
8. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847 [TBL] [Abstract][Full Text] [Related]
9. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
10. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209 [TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory treatment of multiple sclerosis in Norway. Torkildsen Ø; Grytten N; Myhr KM Acta Neurol Scand Suppl; 2007; 187():46-50. PubMed ID: 17419828 [TBL] [Abstract][Full Text] [Related]
13. Chromosomal radiosensitivity in patients with multiple sclerosis. Milenkova M; Milanov I; Kmetska K; Deleva S; Popova L; Hadjidekova V; Groudeva V; Hadjidekova S; Domínguez I Mutat Res; 2013 Sep; 749(1-2):3-8. PubMed ID: 23994714 [TBL] [Abstract][Full Text] [Related]
14. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory treatment of MS in Slovenia. Sega-Jazbec S Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663 [No Abstract] [Full Text] [Related]
16. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Río J; Tintoré M; Sastre-Garriga J; Nos C; Castilló J; Tur C; Comabella M; Montalban X Eur J Neurol; 2012 Jun; 19(6):899-904. PubMed ID: 22289050 [TBL] [Abstract][Full Text] [Related]
17. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
18. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis]. Gusev EI; Boĭko AN; Pozer Ch Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395 [No Abstract] [Full Text] [Related]
19. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969 [TBL] [Abstract][Full Text] [Related]
20. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate. Neuhaus O; Stüve O; Archelos JJ; Hartung HP J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]